A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis.
Fifteen patients with the unequivocal diagnosis of amyotrophic lateral sclerosis (ALS) completed a 1-year randomized double-blind placebo-controlled trial of L-threonine (2 g daily). During the study, patients in the placebo group showed a decline in functional status consistent with the natural history of ALS, which was not statistically different from outcome in the patients in the L-threonine group.
Blin
O
O
Clinique des Maladies du Systeme Nerveux et de l'Appareil Locomoteur, CHU Timone, Marseille.
Pouget
J
J
Aubrespy
G
G
Guelton
C
C
Crevat
A
A
Serratrice
G
G
D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000502:physiology; D012720:Severity of Illness Index; D013912:Threonine / Q000494:pharmacology / Q000627:therapeutic use*
D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; D017981:Receptors, Neurotransmitter; D013912:Threonine